GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (CHIX:NOVOBc) » Definitions » Cyclically Adjusted PS Ratio

Novo Nordisk A/S (CHIX:NOVOBC) Cyclically Adjusted PS Ratio : 27.93 (As of May. 17, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Novo Nordisk A/S Cyclically Adjusted PS Ratio?

As of today (2024-05-17), Novo Nordisk A/S's current share price is kr911.30. Novo Nordisk A/S's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was kr32.63. Novo Nordisk A/S's Cyclically Adjusted PS Ratio for today is 27.93.

The historical rank and industry rank for Novo Nordisk A/S's Cyclically Adjusted PS Ratio or its related term are showing as below:

CHIX:NOVOBc' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 8.17   Med: 11.73   Max: 29.45
Current: 28.37

During the past years, Novo Nordisk A/S's highest Cyclically Adjusted PS Ratio was 29.45. The lowest was 8.17. And the median was 11.73.

CHIX:NOVOBc's Cyclically Adjusted PS Ratio is ranked worse than
88.11% of 513 companies
in the Biotechnology industry
Industry Median: 5.51 vs CHIX:NOVOBc: 28.37

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Novo Nordisk A/S's adjusted revenue per share data for the three months ended in Mar. 2024 was kr14.618. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is kr32.63 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Novo Nordisk A/S Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Novo Nordisk A/S's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Cyclically Adjusted PS Ratio Chart

Novo Nordisk A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.28 10.42 16.05 17.24 22.72

Novo Nordisk A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.19 19.08 21.53 22.72 27.39

Competitive Comparison of Novo Nordisk A/S's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Novo Nordisk A/S's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk A/S's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novo Nordisk A/S's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Novo Nordisk A/S's Cyclically Adjusted PS Ratio falls into.



Novo Nordisk A/S Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Novo Nordisk A/S's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=911.30/32.63
=27.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novo Nordisk A/S's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Novo Nordisk A/S's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=14.618/118.4000*118.4000
=14.618

Current CPI (Mar. 2024) = 118.4000.

Novo Nordisk A/S Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 4.101 99.700 4.870
201409 4.242 99.700 5.038
201412 4.722 99.400 5.625
201503 4.838 100.200 5.717
201506 5.236 100.300 6.181
201509 5.209 100.200 6.155
201512 5.667 99.800 6.723
201603 5.335 100.200 6.304
201606 5.404 100.600 6.360
201609 5.440 100.200 6.428
201612 5.878 100.300 6.939
201703 5.690 101.200 6.657
201706 5.830 101.200 6.821
201709 5.389 101.800 6.268
201712 5.685 101.300 6.645
201803 5.513 101.700 6.418
201806 5.637 102.300 6.524
201809 5.738 102.400 6.635
201812 6.181 102.100 7.168
201903 6.127 102.900 7.050
201906 6.301 102.900 7.250
201909 6.379 102.900 7.340
201912 6.858 102.900 7.891
202003 7.193 103.300 8.244
202006 6.398 103.200 7.340
202009 6.622 103.500 7.575
202012 6.911 103.400 7.914
202103 7.299 104.300 8.286
202106 7.163 105.000 8.077
202109 7.753 105.800 8.676
202112 8.358 106.600 9.283
202203 9.204 109.900 9.916
202206 9.065 113.600 9.448
202209 10.043 116.400 10.216
202212 10.634 115.900 10.863
202303 11.825 117.300 11.936
202306 12.060 116.400 12.267
202309 13.083 117.400 13.194
202312 14.720 116.700 14.934
202403 14.618 118.400 14.618

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Novo Nordisk A/S  (CHIX:NOVOBc) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Novo Nordisk A/S Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk A/S (CHIX:NOVOBC) Business Description

Address
Novo Alle 1, Bagsvaerd, DNK, DK-2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk A/S (CHIX:NOVOBC) Headlines

No Headlines